A B S T R A C T The human hepatoma cell line, PLC/ PRF/5, which is persistently infected with hepatitis B virus (HBV), has integrated HBV-DNA, secretes HBV surface antigen (HBsAg), and does not grow readily in congenitally athymic (nu/nu) mice. The present investigation was undertaken to ascertain whether the low tumorigenicity of this cell line was governed by a host immune response and/or was related to expression of HBsAg. Subcutaneous injection of 4-5 X 106 cells into BALB/c nude mice produced localized encapsulated tumors with morphologic features of primary hepatocellular carcinoma in 25% of the animals within 29-40 d. No tumor growth was observed at lower cell inocula. In contrast, SK-HEP-1, an HBV-negative human hepatoma cell line, produced tumors at 1-5 X 10' cells inocula in 66% of the animals. Immunosuppression of mice with antilymphocyte serum (ALS) or irradiation increased tumor incidence in mice inoculated with 1 X 106 PLC/PRF/ 5 cells to almost 100% and produced local invasiveness. Immunosuppression also reduced the latency, i.e., time to tumor appearance, and increased mean tumor weight. These results suggest that tumorigenicity was limited by the host immune response.
anti-mouse interferon globulin (anti-IFN). When 2 X 106 cells were injected, tumor growth occurred in 75% of anti-IFN-treated mice, whereas controls injected with the same number of cells, but not receiving anti-IFN, failed to develop tumors. The tumors in the anti-IFN-treated mice were highly invasive and the latency period until tumor appearance was reduced to [3] [4] [5] d. An inverse correlation was found between susceptibility of the hepatoma cells to natural killer (NK) activity in vitro and resistance to tumor growth in vivo. In vitro cytotoxicity for PLC/PRF/5 cells was eliminated by anti-NK 1.1 and complement, establishing the effector cell as an NK cell. NK (1, 2) , and in geographical areas where HBV is endemic, such as the Far East, Southeast Asia, and the Mediterranean Basin, HBsAg carriers represent 5-15% of the general population (2, 3) . In recent years, evidence has accumulated that HBV is etiologically associated with primary hepatocellular carcinoma (PHC) (2, 3) . Epidemiological studies indicate that in areas where HBV is endemic, 40-90% of patients with hepatocellular carcinoma are HBsAg carriers and that the tumor incidence is 20-200 times higher in carriers than in the general population (2, 3) . Our ability to study the pathophysiology, immunopathology, and molecular biology of HBV infection and its relation to PHC has been enhanced recently by the establishment of human hepatoma cell lines that secrete HBsAg (4, 5) .
Recently, we and others have characterized one of these human hepatoma cell lines, PLC/PRF/5, which is persistently infected with HBV. As shown by molecular hybridization studies, this cell line contains four to six copies per cell of integrated HBV 10% fetal calf serum (FCS), 10 mM nonessential amino acids, 2 mM L-glutamine, penicillin (100 ,ug/ml), streptomycin (100 ,ug/ml), and fungizone (2.5 jg/ml).
YAC-1 cells, derived from a Moloney leukemia virus-induced lymphoma of A/Sn mice (21) , were maintained in continuous suspension culture in RPMI 1640 medium (Gibco Laboratories) supplemented with 10% FCS, L-glutamine, and antibiotics as above. HeLa-MS, a HeLa cell line persistently infected with measles virus, was obtained from Dr. John Holland (University of California, San Diego) and was grown as monolayers in MEM supplemented with 8% calf serum (14, 22) .
Mouse fibroblasts (L929), used for IFN assays, were grown on Dulbecco's-modified Eagle's medium (DME) supplemented with 10% FCS, glutamine, and antibiotics, and human trisomic-21 skin fibroblasts (Detroit 532; American Type Cell Culture Collection, Rockville, MD), used for human IFN assay, were grown on RPMI 1640 medium supplemented with 10% FCS, glutamine, and antibiotics.
Preparation of cell suspensions for injection Subconfluent cultures were trypsinized with trypsin-EDTA, and cell viability was determined by trypan blue exclusion. The cells were centrifuged, resuspended in serum-free medium, and then injected subcutaneously at different concentrations into the flank region of nude mice (7, 14) .
Detection and evaluation of tumor growth
Mice were examined daily for tumor appearance. Mouse weight was monitored at the beginning and end of experiments. Tumors were measured with a caliper at the longest longitudinal and horizontal axis and tumor volume was expressed in cubic millimeters. At the end of each experiment, mice were autopsied; tumor, liver, spleen, lungs, kidneys, lymph nodes, and bone marrow were fixed in 10% buffered formaldehyde and processed as described previously (7) . Results were evaluated by three independent investigators. Tumor (15) . Anti-IFN globulin. Sheep anti-mouse IFN serum (globulin fraction) was prepared as previously described (23, 24) .
The globulin at a dilution of 1:1,000, completely neutralized 200 U of mouse IFNa. Sheep antiserum to the contaminants in the IFN preparation (AC), which lacked anti-IFN activity, was used as a control. Both the anti-IFN serum and the AC serum were diluted 1:3 with phosphate-buffered saline (PBS) and absorbed with a one-third volume of packed BALB/c spleen cells and erythrocytes for 30 min at 4°C. Mice were injected intravenously with 0.1 ml of anti-IFN or AC serum concomitantly with the inoculation of tumor cells. Mice received a second injection of anti-IFN or AC serum 7 d later.
There was no mortality in groups treated with anti-IFN or with AC serum alone.
Preparation of effector cells
Spleens from tumor-bearing or untreated nude mice were passed through a fine cellector sieve (Bellco Glass, Inc., Vineland, NJ), washed three times with PBS and resuspended in MEM plus 10% FCS at a concentration of 1 X 107 cells/ml. Spleen cells nonadherent to nylon wool were obtained according to the method of Julius et al. (25) 
Natural cytotoxicity assay
Cytotoxic activity of mouse spleen cells against various target cells was performed as described by Minato et al. (15) . Briefly, adherent target cells (PLC/PRF/5 or SK-HEP-1) were trypsinized, washed once in complete medium, and labeled with 100 uCi of 5"Cr (sodium salt, sp act 300-650 mCi/mmol, Amersham Corp., Arlington Heights, IL) for 1 h at 37°C in 5% CO2 with periodic gentle agitation. Cells were washed three times, seeded in flat-bottomed microtiter wells at a density of 2 X 104 cells/well and incubated overnight. YAC-1 cells were labeled as described above and added to U-bottomed microtiter plates at a concentration of 1 X 104 cells/well. Effector spleen cell suspensions from tumor-bearing or untreated mice were added at ratios of 100:1, 50:1, and 25:1, centrifuged (100 g for 2 min), and incubated for 8 h for hepatoma cell lines or 4 h for YAC-1 cells. After incubation, the plates were centrifuged and 0.1 ml of the supernatant fraction was harvested from each well for determination of 51Cr release. For maximal release, 0.1 ml of 2 N HCI was added to each well and specific release was calculated as previously described (15) . Spontaneous 51Cr release was 20.2±0.9% (n = 23) for PLC/ PRF/5 cells and 17.3±1.2% (n = 5) for SK-HEP-1 cells after 8-h incubation, and 20.8±4.1% (n = 5) for YAC-1 cells after 4-h incubation. In some experiments, cytotoxic activity of effector cells was determined by linear regression analysis of percent cytotoxicity against three effector/target ratios and was expressed as lytic units (LU) per 107 spleen cells (27) . 1 LU was defined as the number of effector cells required to produce 20% specific lysis of 2 X 104 hepatoma cells.
IFN induction by mixed lymphocyte-tumor cell cultures (MLTC)
Inc., McLean, VA). The medium, was removed and 1-2 X 10' normal BALB/c nu/nu spleen cells in 1 ml of DME plus 10% FCS were added to the monolayers of hepatoma cells. After (Tables I and II) . The number of cells required to produce tumors was reduced from 4-5 X 10' to 1 X 106 and tumor frequency was increased to virtually 100%. The latency period was shortened considerably, as tumors were palpable and visible within 3-5 d (Table I) dependent, cell-mediated cytotoxicity (ADCC) response, we added monoclonal antibodies against HBsAg (28) to mouse spleen cells and saw no increase in cytotoxic activity against PLC/PRF/5 cells (data not shown), although they are lytic in the presence of complement (28) . As shown in Fig. 1 , a minor peak of increased spleen cell cytotoxicity in tumor-bearing mice was noted on day 3, reappeared on day 10, remained at a constant level for 4 d (days 12-15) and then decreased rapidly. After filtration of spleen cells through nylon wool, 70% of the cytotoxic activity against the same target cells observed on day 14 was retained. By 22 d after tumor cell injection, spleen cell cytotoxic activity was reduced to control levels, concomitant with growth of large tumors. As shown in Fig. 2 iments) after treatment with anti-NK 1.1 serum and complement and by 40% using monoclonal anti-Thy 1.1 serum and complement (four experiments). We refer to the effector cell in this system as an NK cell, probably of the NKT subset (29) . Mice injected with 106 HeLa-Ms cells or with 100 ug poly I:poly C, both of which are known to augment NK activity, showed enhanced splenic cytotoxic activity against PLC/PRF/ 5 and YAC-1 cells (Table V) .
Regulation of effector cells by IFN. On the basis of previous studies of persistently infected tumor cells (15, 24) , it seemed possible that IFN was responsible for the augmentation of NK activity seen against both PLC/PRF/5 and YAC-1 tumor cells. Consequently, mouse IFN was measured in supernatants of PLC/ PRF/5 cells co-cultured with mouse spleen cells and elevated titres were found but not with SK-HEP-1 cells or purified HBsAg co-cultured with mouse spleen cells (Table VI) . These results correlate well with the selectivity of cytotoxic activity for PLC/PRF/5 targets. Interestingly, supernatants from SK-HEP-1 cultures, but not PLC/PRF/5, contained detectable levels of human IFN (Table VI) . 
DISCUSSION
A wide variety of human tumors grow in athymic nude mice, and these animals have been used to assess tumorigenicity of various cell lines as models for experimental chemo-and immunotherapy. Therefore, a comparative investigation of the tumorigenicity of PLC/PRF/5 and SK-HEP-1 cells in these mice was performed. Preliminary observations indicated that athymic nude mice actively suppress growth and tumor formation of PLC/PRF/5 cells (7). In contrast to SK-HEP-1 cells, which were highly malignant in BALB/c nu/nu as were other neoplastic cell lines (14, 15, 18) (14, 15) . It was shown subsequently that normal nude mice exhibit splenic cytotoxicity against virus-infected tumor cells in vitro but not against the uninfected cells, and that the cell responsible for this cytotoxicity appears to be an NK cell regulated by IFN (15, 17) . The IFN-regulated NK response in athymic nude mice was abolished by injection of anti-IFN serum resulting in the augmentation of the tumorigenic potential of virus persistently infected tumor cells (24) . In the present studies, in vitro analysis of the cytotoxic activity of spleen cells from normal or PLC/PRF/5-inoculated nude mice indicated that PLC/PRF/5 cells, but not SK-HEP-1 cells, are susceptible to lysis by spleen cells from PLC/PRF/5-injected mice (Table IV) . Two peaks of augmented splenic cytolytic activity were seen, a minor one on day 3 and a major one by 12-14 d following inocu-lation. Both peaks were abolished by immunosuppression by x-irrad, ALS, or anti-IFN serum.
Evidence for the role of murine IFN in restriction of growth of PLC/PRF/5 tumor cells was derived from both in vitro and in vivo studies. Splenic cytotoxic activity correlated with the ability of PLC/PRF/5 cells to induce mouse IFN but not human IFN when co-cultivated with normal mouse spleen cells (Table  VI) . Since the species specificity for the action of IFN is well established (32) , and since there was no correlation with the secretion of human IFN by SK-HEP-1 cells and susceptibility to lysis, these results suggest that the restriction of growth of PLC/PRF/5 cells in nude mice resulted from augmentation of a host response regulated by mouse IFN.
Several in vivo studies also point to the relevance of murine IFN to restriction of PLC/PRF/5 cell growth in nude mice. The splenic cytolytic activity of nude mice against PLC/PRF/5 cells was significantly augmented by injection of the nonspecific IFN inducer, poly I:poly C. Even more dramatically, treatment of nude mice with high titer antiserum to mouse IFN resulted in rapid growth and invasiveness of PLC/ PRF/5 cells. Anti-mouse-IFN treatment was more effective than the other immunosuppressive treatments. Anti-IFN-treated mice developed visible tumors within 3-5 d, whereas none of the other mice showed tumors. Furthermore, tumor frequency was increased to 100%, required inoculum dosages were decreased and tumor weight was increased. Most striking was the increase in invasive potential of PLC/PRF/5 cells after anti-IFN treatment. In these respects, the restriction of growth of this DNA virus-infected tumor cell line by host responses in nude mice parallels the IFN-NK celldependent resistance to RNA virus persistently infected tumor cell lines (14, 15, 17, 24) .
From various experiments, we infer that the effector cell in this system is an NK cell. Cytotoxicity against PLC/PRF/5 cells was diminished by treatment with NK 1.1 and complement and with anti-Thy 1 plus complement, which would be the characteristic phenotype of activated NKT cells (29) . ADCC seemed improbable, since killing of PLC/PRF/5 could not be achieved in vitro by addition of monoclonal or polyclonal anti-HBs sera to normal spleen cells in vitro (data not shown).
In analyzing the activation of IFN-regulated mechanisms, it is unclear whether HBsAg expression on the PLC/PRF/5 cell membrane or secretion of HBsAg (a glycoprotein) into the medium is responsible for the immunologic response restricting growth of these cells. Cytoplasmic HBsAg was previously demonstrated in 90% of the PLC/PRF/5 cells in culture and in >50% of tumor cells in BALB/c nude mice (7, 33 The present findings suggest that the HBV-infected hepatoma cell line, PCL/PRF/5, is restricted in its growth in nude mice by a mechanism(s) bearing many similarities to that causing restriction of growth of RNA virus persistently infected tumor cells (14, 15, 17, 24) . This system may therefore prove useful in probing the immunologic mechanisms of defense against human hepatomas with or without HBV infection. These observations may also be utilized to study the effects of chemotherapy and immunotherapy on human hepatoma, using PLC/PRF/5 as the experimental model. In view of the recent findings that human IFN, with or without adjuvant chemotherapy, may inhibit the replication of HBV (36) 
